• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
SMI-4a

SMI-4a

Product ID S4932
Cas No. 438190-29-5
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $84.00 In stock
10 mg $144.00 In stock
25 mg $295.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

SMI-4a is a thiazolidine inhibitor of Pim kinase that displays anticancer chemotherapeutic activity. SMI-4a prevents phosphorylation of eIF4B and suppresses tumor growth in animal models of cancer. In myeloid and lymphoid cells, SMI-4a induces G1 phase cell cycle arrest, apoptosis, and cell death. Additionally, this compound delays tumor growth in animal models of precursor T-cell lymphoblastic leukemia/lymphoma.

Product Info

Cas No.

438190-29-5

Purity

≥99%

Formula

C11H6F3NO2S

Formula Wt.

273.23

IUPAC Name

(5Z)-5-[3-(Trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione

Solubility

DMSO 55 mg/mL (201.29 mM) Ethanol 32 mg/mL (117.11 mM) Water Insoluble

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

S4932 MSDS PDF

Info Sheet

S4932 Info Sheet PDF

References

Yang J, Wang J, Chen K, et al. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res. 2013 Aug 1;73(15):4898-908. PMID: 23749639.

Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28;115(4):824-33. PMID: 19965690.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O4400

    Olanzapine

    AMPK activator, D1-4, 5-HT1A/2/3/6/7, M1-5 mACh...

    ≥99%
  • V0275

    [Arg8]-Vasotocin

    Peptide, oxytocin-vasopressin analog.

    ≥95%
  • B1652

    Benzo[a]pyrene

    Polycyclic aromatic hydrocarbon (PAH) found in ...

    ≥98%
  • H9711

    (Z)-4-Hydroxytamoxifen

    SERM.

    ≥98%
  • S3476

    Sitagliptin Phosphate Monohydrate

    DPP4 inhibitor.

    ≥98%
  • H9716

    (E,Z)-4-Hydroxytamoxifen

    Selective estrogen receptor modulator.

    ≥97%
  • I7459

    1-Isothiocyanato-8-(methylsulfinyl)-octane

    ITC found in Nasturtium officinale (watercress)...

    ≥98%
  • B8363

    Bupropion Hydrochloride

    α3β2, α3β4, α4β2 nAChR antagonist, indire...

    ≥98%
  • M704789

    MRTX1133

    KRAS inhibitor

    ≥98%
  • J3204

    E-JIB-04

    Jumonji histone demethylase inhibitor.

    ≥98%
  • C6955

    Cromolyn Sodium

    Mast cell destabilizer; potential TRP antagonis...

    ≥99%
  • R3312

    Ridaifen A Dihydrochloride

    Tamoxifen derivative; potential proteasome inhi...

    ≥98%
  • B5871

    Bortezomib

    Proteasome inhibitor.

    ≥98%
  • M0040

    M40

    Peptide; galanin antagonist.

    ≥95%
  • J3205

    Z-JIB-04

    Jumonji histone demethylase inhibitor.

    ≥98%
  • M1685

    Mevastatin

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • O4532

    Oligomycin B

    Macrolide; F1F0 ATP synthase inhibitor.

    ≥97%, TLC, HPLC
  • P4132

    PKI-402

    p110α PI3K and mTOR inhibitor.

    ≥98%
  • B0396

    BAY80-6946

    p110α PI3K inhibitor.

    ≥98%
  • G5216

    GNE-7915

    LRRK2 inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only